2014
Implant and Clinical Characteristics for Pediatric and Congenital Heart Patients in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry
Jordan CP, Freedenberg V, Wang Y, Curtis JP, Gleva MJ, Berul CI. Implant and Clinical Characteristics for Pediatric and Congenital Heart Patients in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry. Circulation Arrhythmia And Electrophysiology 2014, 7: 1092-1100. PMID: 25287482, DOI: 10.1161/circep.114.001841.Peer-Reviewed Original ResearchConceptsNew York Heart Association classPrimary preventionSecondary preventionPediatric patientsAssociation classLEAD patientsGreat vesselsNational Cardiovascular Data Registry Implantable Cardioverter Defibrillator RegistryHigher New York Heart Association classImplantable Cardioverter-Defibrillator RegistryImplantable cardioverter defibrillator implantationNational Cardiovascular Data RegistryImplantable cardioverter-defibrillator indicationsImplantable cardioverter-defibrillator (ICD) proceduresCongenital heart patientsCardioverter-defibrillator implantationStructural heart diseaseHigh rateLead implantsOverall registryVentricle patientsClinical characteristicsDefibrillator implantationCHD typesCommon ventricleIMPLANT AND CLINICAL CHARACTERISTICS FOR PRIMARY VERSUS SECONDARY PREVENTION ICD INDICATIONS FOR PEDIATRIC AND CONGENITAL HEART PATIENTS IN THE NCDR®
Jordan C, Freedenberg V, Curtis J, Wang Y, Gleva M, Berul C. IMPLANT AND CLINICAL CHARACTERISTICS FOR PRIMARY VERSUS SECONDARY PREVENTION ICD INDICATIONS FOR PEDIATRIC AND CONGENITAL HEART PATIENTS IN THE NCDR®. Journal Of The American College Of Cardiology 2014, 63: a526. DOI: 10.1016/s0735-1097(14)60526-x.Peer-Reviewed Original Research
2004
Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke
Sokol SI, Portnay EL, Curtis JP, Nelson MA, Hebert PR, Setaro JF, Foody JM. Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke. Neurology 2004, 63: 208-213. PMID: 15277610, DOI: 10.1212/01.wnl.0000130360.21618.d0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin-Converting Enzyme InhibitorsAnimalsBrainChronic DiseaseDouble-Blind MethodDrug Evaluation, PreclinicalEndothelium, VascularFibrinolysisHemostasisHumansInflammationMiddle AgedNerve RegenerationRandomized Controlled Trials as TopicRatsReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Renin-Angiotensin SystemSecondary PreventionStrokeTreatment OutcomeConceptsRenin angiotensin aldosterone systemRAAS modulationRecurrent strokeAldosterone systemCerebrovascular eventsStroke preventionSecondary preventionACE inhibitorsCerebrovascular diseaseAngiotensin II type 1 receptor blocker therapiesBlood pressure-independent mechanismsMajor public health concernReceptor blocker therapyRecurrent cerebrovascular eventsRecurrent stroke preventionAngiotensin aldosterone systemBlood pressure reductionSecondary stroke preventionRecurrent cardiac eventsPressure-independent mechanismsVascular structural changesOngoing clinical trialsNew treatment strategiesPublic health concernBlocker therapy